Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise on Clinical Progress

Last update: Aug 7, 2025

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) reported its second-quarter 2025 financial results, with a narrower-than-expected loss per share, prompting a positive after-hours market reaction. The company posted a loss of $0.10 per share, beating analyst estimates of a $0.14 loss. Revenue for the quarter came in at $0.0, in line with expectations.

Key Financial Highlights

Earnings Per Share (EPS): Reported at -$0.10, surpassing the consensus estimate of -$0.14.
Revenue: Remained at $0.0, matching projections, as the company has no commercialized products yet.
Market Reaction: Shares rose ~5.8% in after-hours trading, reflecting investor optimism over the improved earnings performance.

Clinical Progress and Business Update

The earnings release highlighted promising data from the Phase 1 clinical trial of soquelitinib, Corvus’s lead candidate for atopic dermatitis. Key takeaways from the trial include:

Earlier and deeper responses in cohort 3 compared to earlier cohorts.
Clinically meaningful reduction in itch observed as early as day 8.
Continued progress in evaluating ITK inhibition as a novel immunotherapy approach for autoimmune and oncological conditions.

While the company did not provide a formal financial outlook in the press release, analysts currently estimate:

Q3 2025 EPS: -$0.15 (vs. Q2’s -$0.10).
Full-year 2025 EPS: -$0.34, with no expected revenue.

Market Performance Context

Despite the post-earnings uptick, CRVS has seen mixed performance in recent weeks:

Last week: -4.8%
Last two weeks: -10.7%
Last month: Flat (-0.2%)

The after-hours surge suggests that investors are encouraged by the narrower loss and positive clinical developments, though long-term sentiment will depend on further trial progress and eventual commercialization prospects.

For more detailed earnings estimates and historical performance, see Corvus Pharmaceuticals’ earnings data.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.